[go: up one dir, main page]

DK2041576T3 - Differentiel cytokinekspression i humane cancere - Google Patents

Differentiel cytokinekspression i humane cancere

Info

Publication number
DK2041576T3
DK2041576T3 DK07764767.5T DK07764767T DK2041576T3 DK 2041576 T3 DK2041576 T3 DK 2041576T3 DK 07764767 T DK07764767 T DK 07764767T DK 2041576 T3 DK2041576 T3 DK 2041576T3
Authority
DK
Denmark
Prior art keywords
human cancers
cytokine expression
differential cytokine
differential
expression
Prior art date
Application number
DK07764767.5T
Other languages
English (en)
Inventor
Christian Gieffers
Oliver Hill
Giorgio Stassi
Matilde Todaro
Meinolf Thiemann
Original Assignee
Apogenix Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix Gmbh filed Critical Apogenix Gmbh
Application granted granted Critical
Publication of DK2041576T3 publication Critical patent/DK2041576T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK07764767.5T 2006-06-21 2007-06-21 Differentiel cytokinekspression i humane cancere DK2041576T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06012754 2006-06-21
PCT/EP2007/005480 WO2007147600A2 (en) 2006-06-21 2007-06-21 Differential il-4 and/or il-10 cytokine expression in human cancer

Publications (1)

Publication Number Publication Date
DK2041576T3 true DK2041576T3 (da) 2011-12-05

Family

ID=38359749

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07764767.5T DK2041576T3 (da) 2006-06-21 2007-06-21 Differentiel cytokinekspression i humane cancere

Country Status (12)

Country Link
US (1) US20090324616A1 (da)
EP (1) EP2041576B1 (da)
JP (1) JP2010514409A (da)
CN (1) CN101529253A (da)
AT (1) ATE520032T1 (da)
AU (1) AU2007263265A1 (da)
BR (1) BRPI0713484A2 (da)
CA (1) CA2656379A1 (da)
DK (1) DK2041576T3 (da)
ES (1) ES2371287T3 (da)
RU (1) RU2009101783A (da)
WO (1) WO2007147600A2 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2646626A1 (en) * 2006-03-22 2007-09-27 Apogenix Gmbh Antibody specific for human il-4 for the treatment of cancer
US20100086515A1 (en) * 2006-07-06 2010-04-08 Apogenix Gmbh Human il-4 muteins in cancer therapy
HK1207095A1 (en) * 2012-07-18 2016-01-22 阿珀吉尼科斯股份公司 Composition comprising a mixture of cd95-fc isoforms
US11299528B2 (en) 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
RU2716821C2 (ru) * 2014-10-24 2020-03-17 Калиди Биотерапьютикс, Инк. Комбинированный иммунотерапевтический подход к лечению рака
EA201800148A1 (ru) 2015-08-11 2019-01-31 Калиди Биотерапьютикс, Инк. Оспенная вакцина для лечения рака
CA3008392C (en) 2015-12-17 2021-11-09 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
EP3439687A1 (en) 2016-04-07 2019-02-13 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
WO2018097646A1 (ko) * 2016-11-24 2018-05-31 이형근 질환의 진단용 조성물
WO2019051128A1 (en) * 2017-09-06 2019-03-14 Fred Hutchinson Cancer Research Center SPECIFIC STREP LABEL CHIMERIC RECEPTORS AND USES THEREOF
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) * 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
US6534051B1 (en) * 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
JPH09502708A (ja) 1993-09-07 1997-03-18 スミスクライン・ビーチャム・コーポレイション Ｉｌ４により伝達される疾患の治療に有用な組み換え型ｉｌ４抗体
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
US6159937A (en) * 1994-07-05 2000-12-12 Steeno Research Group A/S Immunomodulators
AU3382595A (en) * 1994-07-29 1996-03-04 Smithkline Beecham Corporation Novel compounds
US6664227B1 (en) * 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US20030124125A1 (en) * 1996-04-05 2003-07-03 South Alabama Medical Science Foundation Oncofetal antigen specific T-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific CD4, CD8 cytotoxic and suppressor T cells and interleukin-10
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
EP1029550A4 (en) * 1997-11-10 2001-09-26 Mochida Pharm Co Ltd PREVENTIVE AND THERAPEUTIC DRUGS FOR DIFFUSED PULMONARY CONDITIONS
JPH11312463A (ja) * 1998-04-28 1999-11-09 Hitachi Ltd 配線基板およびそれを用いたガス放電型表示装置
EP1283722A1 (en) * 2000-03-31 2003-02-19 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
AU2001273413A1 (en) * 2000-07-12 2002-01-21 Immunex Corporation Method for treating cancer using an interleukin- 4 antagonist
US20040023338A1 (en) * 2001-10-26 2004-02-05 Heavner George A. IL-4 mutein proteins, antibodies, compositions, methods and uses
CA2464695A1 (en) * 2001-10-26 2003-05-01 Centocor, Inc. Il-13 mutein proteins, antibodies, compositions, methods and uses
EP1444989A1 (en) * 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
MX2007005866A (es) * 2004-11-17 2007-11-12 Amgen Inc Anticuerpos monoclonales totalmente humanos para il-13.
US20070122855A1 (en) * 2005-11-28 2007-05-31 Targetgen Inc. Methods for diagnosing hepatocellular carcinoma
CA2646626A1 (en) * 2006-03-22 2007-09-27 Apogenix Gmbh Antibody specific for human il-4 for the treatment of cancer
US20100086515A1 (en) * 2006-07-06 2010-04-08 Apogenix Gmbh Human il-4 muteins in cancer therapy

Also Published As

Publication number Publication date
WO2007147600A2 (en) 2007-12-27
ATE520032T1 (de) 2011-08-15
BRPI0713484A2 (pt) 2012-11-06
CA2656379A1 (en) 2007-12-27
US20090324616A1 (en) 2009-12-31
JP2010514409A (ja) 2010-05-06
RU2009101783A (ru) 2010-07-27
ES2371287T3 (es) 2011-12-29
EP2041576B1 (en) 2011-08-10
WO2007147600A3 (en) 2008-04-10
CN101529253A (zh) 2009-09-09
EP2041576A2 (en) 2009-04-01
AU2007263265A1 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
DK2041576T3 (da) Differentiel cytokinekspression i humane cancere
PH12014502507A1 (en) Anti-angiogenesis therapy for the treatment of breast cancer
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
ZA201604468B (en) Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
CY1118714T1 (el) Υψηλης συγγενειας ανθρωπινα αντισωματα κατα του ανθρωπινου ενεργοποιουμενου απο πρωτεαση υποδοχεα-2
ATE448232T1 (de) Substituierte heterozyklen
WO2012145535A3 (en) Animal model of human cancer and methods of use
EP2175879A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH PRION PROTEIN
WO2006105252A3 (en) Diagnosis of chronic pulmonary obstructive disease and monitoring of therapy using gene expression analysis of peripheral blood cells
MX2021009247A (es) Metodos, sistemas y kits para tratar enfermedades inflamatorias que se dirigen a il18r1.
WO2008053484A3 (en) Preparation of heavy metal-containing nano-liposomes and their uses in medical therapy
MY179250A (en) Protein biomarkers for soft tissue disease diagnosis and as therapeutic targets for oral care intervention
ATE511551T1 (de) Aus lebendigen tumorzellen ausgewählte aptamere und deren verwendung
WO2009091230A3 (ko) 유방암 모니터링,진단 및 스크리닝용 단백질 마커 및 이를 이용한 유방암 모니터링,진단 및 스크리닝 방법
BRPI0516661A (pt) epitopos antigênicos da interleucina-21, anticorpos relacionados e seu uso no campo medicinal
WO2012109233A3 (en) Methods for predicting recurrence risk in breast cancer patients
CO6612209A2 (es) Terapia antia-agiogénesis para el tratamiento de cáncer de mama previamente tratado
MX356814B (es) Métodos y composiciones para neuroprotección.
EA201500765A1 (ru) Способы лечения сердечно-сосудистых заболеваний
ATE533861T1 (de) Mipol1-etv1-gen-neuanordnungen
PH12015502516A1 (en) Efficacious treatment of nsclc and predictive clinical marker of the responsiveness of a tumour to a treatment
DE602005025231D1 (de) Gene und polypeptide in verbindung mit brustkrebserkrankungen
WO2015067710A3 (en) Tyrp1, a natural mirna sponge, and its use in managing human melanoma aggressiveness